异体树突状细胞融合瘤苗抗骨肉瘤的免疫效应实验
Allogeneic Tumor Vaccine Produced by Electrofusion between Osteosarcoma Cell Line and Dendritic Cells in the Induction of Antitumor Immunity
-
摘要: 目的探讨大鼠异体树突状细胞融合瘤苗诱导的抗骨肉瘤免疫学效应。方法采用Wistar大鼠骨髓来源的DCs与SD大鼠来源的骨肉瘤细胞UMR106通过电穿孔的方法进行融合。经分离纯化后,分别与SD、Wistar大鼠骨髓来源的T淋巴细胞作共同培养,刺激其增殖。采用流式细胞仪对其CD8+,CD4+细胞比例进行检测。MTT法测定细胞毒T淋巴杀瘤活性。结果T淋巴细胞和异体融合瘤苗经过共同培养,T细胞得以显著增殖。异体瘤苗诱导的UMR106特异性CTLs杀瘤效果显著,该效应是由MHC-Ⅰ限制的CD8+细胞发挥作用。结论异体树突状细胞与骨肉瘤细胞融合瘤苗具有显著的刺激T淋巴细胞增殖和诱导特异性CTLs的潜能,为以树突状细胞为基础的免疫治疗领域提供了新的策略,有望在临床骨肉瘤患者中获得广阔的应用前景。Abstract: Objective To investigate the antitumor effects of tumor vaccine produced by electrofusion between rat osteosarcoma cells and allogeneic DCs. Methods We eletrofused Wistar rat bone marrow-derived DCs to SD rat osteosarcoma cells (UMR106) and purified them by monoclonal antibody OX62 and magnetic beads. Coculture of SD or Wistar bone marrow derived T lymphocytes with DC/tumor fusion cells resulted in activation of T cells and the proportion of CD8 +, CD4 + cells was determined using flow cytometry. Then cytot...
下载:
